ReviewCurrent allergy and asthma reports2018
Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic.
Review in Current allergy and asthma reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Burden of and Trends in Urticaria Globally, Regionally, and Nationally from 1990 to 2019: Systematic Analysis.JMIR public health and surveillance · 2023Article
- Omalizumab for the treatment of severe allergic asthma in children: A tale of two.Clinical case reports · 2022Article
- Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia.Frontiers in allergy · 2022Article
- Biologic drugs in chronic spontaneous urticaria.Acta bio-medica : Atenei Parmensis · 2021Review
- Expert consensus on the use of omalizumab in chronic urticaria in China.The World Allergy Organization journal · 2021Review
- Review
- Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.Clinical reviews in allergy & immunology · 2020Review
- A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Observational
- Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey.Postepy dermatologii i alergologii · 2019Article
- Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.The World Allergy Organization journal · 2019Article
- Activation of Human Peripheral Basophils in Response to High IgE Antibody Concentrations without Antigens.International journal of molecular sciences · 2018Article
- Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSince omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017-February 2018. RECENT
findingsOmalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/month; however, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could be augmented (6-8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse. Some biomarkers are being detected. Adjusting omalizumab doses in urticaria patients could enhance efficacy (shortening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.